Oura files for IPO, targeting valuation above $15B
Fidelity InvestmentsCompany
LillyInvestor
Oura Inc. filed an S‑1 on Sept. 12, 2026 to launch an IPO targeting a valuation above $15 billion, with Fidelity and Eli Lilly as anchor investors.
Oura Inc. filed to go public this fall, aiming for a valuation exceeding $15 billion and securing Fidelity and Eli Lilly as cornerstone investors. The smart‑ring maker’s S‑1, released on Sept. 12, 2026, outlines a plan to list on a U.S. exchange and raise a sizable equity tranche to fund continued retail expansion and data‑platform development.
Deal Terms
The filing does not disclose the exact share price or amount of capital to be raised, but the company’s internal projections support a market cap north of $15 billion. Fidelity and Eli Lilly are listed as strategic investors, signaling confidence from both a leading asset manager and a major pharma player in Oura’s health‑data moat. The IPO will convert Oura’s existing private equity stakes into public float, giving early backers liquidity while providing a public market for future growth.
Business Model
Oura reports roughly five million paying customers, each of whom purchases a $349‑$499 ring and a monthly subscription that unlocks deeper analytics. Subscription renewal stands at about 85% after the first year, and 94% of ring buyers opt into the recurring plan. Margins differ sharply: hardware delivers a 47% gross margin, while the subscription business enjoys an 89% margin, making recurring revenue the engine of profitability. Retail distribution now accounts for half of hardware sales, with the ring stocked in Best Buy, Amazon, Target, Costco and Walmart, driving unit sales from 1 million in FY 2024 to 3.1 million in the nine months to June 2026.
CEO Tom Hale, a former SurveyMonkey president, has overseen the retail rollout and is positioning Oura as a data platform rather than a pure hardware play. The prospectus emphasizes an “intelligence platform” built on aggregated biometric data, a narrative that underpins the lofty valuation and differentiates Oura from larger wearables firms that rely on ad‑supported models.
The IPO will give Oura a public‑market runway to fund its ten‑year ambition to sell 85 million rings and reach 45 million paying members, a scale that would eclipse Fitbit’s historic device shipments. Whether the market will price in that growth remains an open question, but the filing marks a decisive shift from a niche health‑tech startup to a publicly traded, data‑centric consumer health company.
Why It Matters
For Oura, the IPO provides a liquidity event that can accelerate its retail penetration and fund the development of its proprietary health‑intelligence platform. Existing competitors such as Fitbit, Apple, and Garmin now face a public company with deep subscription margins and a growing data moat, potentially reshaping pricing dynamics in the wearables space. The backing of Fidelity and Eli Lilly also signals that institutional investors see strategic value in Oura’s health‑data assets, which could spur further M&A interest from pharma or insurance firms seeking direct consumer health insights.
For investors, Oura’s model offers a hybrid of hardware growth and high‑margin SaaS recurring revenue, a combination that has historically commanded premium multiples. The public listing will create a transparent benchmark for valuation multiples in the niche of health‑focused wearables, giving venture capitalists and private equity firms clearer reference points for future funding rounds or exits in adjacent categories.
Key Points
- Oura filed an S‑1 on Sept. 12, 2026 targeting a valuation above $15 billion
- Fidelity and Eli Lilly are anchor investors in the IPO
- The company has ~5 million paying customers with 94% ring‑buyer subscription uptake
- Hardware gross margin is ~47% while subscription margin is ~89%
- Retail now accounts for half of ring sales, driving units from 1 M in FY 2024 to 3.1 M in nine months to June 2026
Analysis
Oura’s IPO sits at the intersection of consumer hardware and high‑margin SaaS, a blend that investors have rewarded with premium multiples in recent years. Assuming a $15 billion market cap and roughly $600 million of trailing twelve‑month subscription revenue, the implied SaaS multiple hovers around 25‑30 x ARR—well above the 10‑15 x range typical for pure hardware firms but in line with data‑rich health platforms. The valuation also reflects the perceived strategic value of Oura’s biometric data set, which could be monetized through partnerships with insurers, pharma, or corporate wellness programs. For operators, the filing underscores the importance of building recurring revenue streams on top of hardware, as subscription margins (≈89%) dwarf hardware margins (≈47%). The retail expansion into mass‑market channels reduces reliance on direct‑to‑consumer sales and improves unit economics, a playbook that other niche wearables may emulate. From an investor perspective, the deal highlights a growing appetite for health‑tech companies that can combine consumer engagement with actionable data, suggesting that future capital will flow toward firms that can replicate Oura’s subscription‑first model while scaling hardware distribution. The public market will now price Oura’s growth assumptions, providing a clear bar for comparable startups seeking exits in the health‑data SaaS space.